Huang Enoch T, Mansouri Jaleh, Murad M Hassan, Joseph Warren S, Strauss Michael B, Tettelbach William, Worth Eugene R
Undersea Hyperb Med. 2015 May-Jun;42(3):205-47.
The role of hyperbaric oxygen (HBO2) for the treatment of diabetic foot ulcers (DFUs) has been examined in the medical literature for decades. There are more systematic reviews of the HBO2/DFU literature than there have been randomized controlled trials (RCTs), but none of these reviews has resulted in a clinical practice guideline (CPG) that clinicians, patients and policy-makers can use to guide decision-making in everyday practice.
The Undersea and Hyperbaric Medical Society (UHMS), following the methodology of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, undertook this systematic review of the HBO2 literature in order to rate the quality of evidence and generate practice recommendations for the treatment of DFUs. We selected four clinical questions for review regarding the role of HBO2 in the treatment of DFUs and analyzed the literature using patient populations based on Wagner wound classification and age of the wound (i.e., acute post-operative wound vs. non-healing wound of 30 or more days). Major amputation and incomplete healing were selected as critical outcomes of interest.
This analysis showed that HBO2 is beneficial in preventing amputation and promoting complete healing in patients with Wagner Grade 3 or greater DFUs who have just undergone surgical debridement of the foot as well as in patients with Wagner Grade 3 or greater DFUs that have shown no significant improvement after 30 or more days of treatment. In patients with Wagner Grade 2 or lower DFUs, there was inadequate evidence to justify the use of HBO2 as an adjunctive treatment.
Clinicians, patients, and policy-makers should engage in shared decision-making and consider HBO2 as an adjunctive treatment of DFUs that fit the criteria outlined in this guideline. The current body of evidence provides a moderate level of evidence supporting the use of HBO2 for DFUs. Future research should be directed at improving methods for patient selection, testing various treatment protocols and improving our confidence in the existing estimates.
几十年来,医学文献一直在探讨高压氧(HBO₂)治疗糖尿病足溃疡(DFU)的作用。关于HBO₂/DFU文献的系统评价比随机对照试验(RCT)更多,但这些评价均未产生临床医生、患者和政策制定者可用于指导日常实践决策的临床实践指南(CPG)。
水下和高压医学协会(UHMS)遵循推荐分级评估、制定和评价(GRADE)工作组的方法,对HBO₂文献进行了这项系统评价,以评估证据质量并生成DFU治疗的实践建议。我们选择了四个关于HBO₂在DFU治疗中作用的临床问题进行综述,并根据瓦格纳伤口分类和伤口年龄(即术后急性伤口与30天或更长时间的不愈合伤口)对患者群体的文献进行了分析。主要截肢和愈合不全被选为感兴趣的关键结局。
该分析表明,HBO₂有利于预防刚接受足部手术清创的瓦格纳3级或更高级别DFU患者以及治疗30天或更长时间后无明显改善的瓦格纳3级或更高级别DFU患者的截肢并促进完全愈合。对于瓦格纳2级或更低级别的DFU患者,没有足够的证据证明使用HBO₂作为辅助治疗是合理的。
临床医生、患者和政策制定者应共同参与决策,并将HBO₂视为符合本指南所述标准的DFU辅助治疗方法。目前的证据体系提供了中等水平的证据支持将HBO₂用于DFU。未来的研究应致力于改进患者选择方法、测试各种治疗方案并提高我们对现有估计值的信心。